Sugi Predict

Sugi Predict / Compounds / SCHEMBL16007189

SCHEMBL16007189

SCHEMBL16007189

O=c1[nH]c(=O)c2c(Cl)ccn2[nH]1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYMP P19971 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ GRIN2D O15399 1/20 0.30
▸ GRIN3B O60391 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ THPO P40225 1/20 0.30
▸ GRIA1 P42261 1/20 0.30
▸ GRIA2 P42262 1/20 0.30
▸ GRIA3 P42263 1/20 0.30
▸ GRIA4 P48058 1/20 0.30
▸ BLM P54132 1/20 0.30
▸ PMP22 Q01453 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ GRIN1 Q05586 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30725405 0.77 CHEK1 (0.34) TYMPGDA
SCHEMBL1269078 0.64 CHEK1 (0.48) KDM4E
SCHEMBL5863360 0.62 PARP1 (0.38) SMN1; SMN2
SCHEMBL29276239 0.60 DAO (0.34) —
SCHEMBL30725398 0.59 ALDH1A1 (0.34) TYMPALDH1A1LMNAMAPTTSHR
SCHEMBL15408051 0.59 PDE3B (0.42) TYMPGRIN2DGRIN3BGRIA1GRIA2
SCHEMBL4052191 0.57 PARP1 (0.39) MEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL18359609 0.55 TNKS (0.35) GDA
SCHEMBL67366 0.54 — —
SCHEMBL7027217 0.53 HTT (0.42) TYMPGDA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE KHORA SPV 1, LLC 2025-05-22 — — US disclosed
EP-4469062-A1 INHIBITORS OF CDK4/6 KINASE Kinnate Biopharma Inc. (US) 2024-12-04 — — EP disclosed
CN-119013030-A Inhibitors of CDK4/6 kinase 金耐特生物制药公司 2024-11-22 — — CN disclosed
CN-117362318-A PB2 inhibitor and preparation method and application thereof 西藏海思科制药有限公司 2024-01-09 — — CN disclosed
CN-115698011-B PB2 inhibitor and preparation method and application thereof 四川海思科制药有限公司 2023-10-20 — — CN disclosed
US-11753413-B2 Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-09-12 — — US disclosed
US-11753413-B2 Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-09-12 — — US disclosed
US-11753413-B2 Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors INCYTE CORPORATION (US) 2023-09-12 — — US disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 — — US disclosed
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-24 — — US disclosed
EP-4180434-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 — — EP disclosed
EP-4180434-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 — — EP disclosed
CN-115698011-A PB2 inhibitor and preparation method and application thereof 四川海思科制药有限公司 2023-02-03 — — CN disclosed
WO-2021257863-A1 PYRROLOTRIAZINE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION (US) 2021-12-23 — — WO disclosed
US-20210395257-A1 PYRROLOTRIAZINE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION 2021-12-23 — — US disclosed
WO-2021257863-A1 PYRROLOTRIAZINE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION (US) 2021-12-23 — — WO disclosed
US-20210395257-A1 PYRROLOTRIAZINE COMPOUNDS AS JAK2 V617F INHIBITORS INCYTE CORPORATION 2021-12-23 — — US disclosed
EP-2970296-B1 PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-12-21 — — EP disclosed
US-9050345-B2 Pyrrolotriazines as potassium ion channel inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-09 — — US disclosed
US-20140256719-A1 PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256719-A1 PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS KCNJ4, KCNJ2, KCNA4 TYMP 4118/4885KDM4E 1004/4885MEN1 2790/4885
US-20230265107-A1 PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP11B2, WEE2, CYP11B1 TYMP 363/4885KDM4E 4592/4885MEN1 1960/4885
US-11753413-B2 Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors JAK2, JAK1, JAK3 TYMP 1442/4885KDM4E 1014/4885MEN1 3327/4885
US-20250163063-A1 INHIBITORS OF CDK4/6 KINASE CDK4, CDK6, CDK2 TYMP 148/4885KDM4E 926/4885MEN1 2684/4885
US-20210395257-A1 PYRROLOTRIAZINE COMPOUNDS AS JAK2 V617F INHIBITORS JAK2, JAK1, JAK3 TYMP 1096/4885KDM4E 1059/4885MEN1 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.